🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Moderna, Inc. MRNA SPX

Healthcare · Biotechnology · United States
https://www.modernatx.com

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

READ MORE ›
$47.19
+77.67% 1Y

Market & Price

Market Cap
$18.72B
Current Price
$47.19
High / Low (52W)
$57.80 / $22.36
Beta
1.06

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$21.95
Price to Book
2.15
P/S
8.42
EV/EBITDA
-6.45
Dividend Yield
-

Profitability & Returns

ROCE
-26.64%
ROE
-36.56%
ROA
-13.09%
Profit Margin
-
Op Margin
-
EPS (Latest Qtr)
$-3.40
EPS (TTM)
$-8.14

Balance Sheet & Liquidity

Debt/Equity
0.18
Quick Ratio
2.23
Current Ratio
2.41
Debt
$1.30B
Total Assets
$12.34B
Current Assets
$6.54B
Working Capital
$4.56B

Ownership

Promoter Holding
7.30%
Chg in Prom Hold
-
FII / Inst Holding
78.83%
Chg in FII Hold
-0.01%

Financial Snapshot

Enterprise Value
$14.82B
Total Revenue (TTM)
$2.22B
EBITDA
$-2.30B
Free Cash Flow
$-20.00M
Operating Cash Flow
$-1.47B
Shares Outstanding
396.79M
Gross Margin
-69.89%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
-53.30%
Profit 5Y
-44.58%
Revenue (YoY)
260.20%
Earnings (YoY)
-

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -53.3% CAGR over 5 years.
  • Earnings shrank at -44.6% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 MRNA Moderna, Inc. SPX 47.19 - $18.72B - -26.64% -36.56% -53.30% -44.58%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue --------16.02M13.08M17.05M---------3.36B1.86B344.00M1.83B167.00M241.00M1.86B-107.00M137.00M1.00B676.00M389.00M
Cost of Revenue ----------------------------90.00M119.00M207.00M452.00M955.00M
Gross Profit ----------------------------17.00M18.00M795.00M224.00M-566.00M
Operating Expenses ----------------------------1.07B925.00M1.05B1.08B822.00M
Operating Income -65.46M-94.19M-67.87M-41.83M-77.40M-97.02M-85.82M-153.03M-141.64M-143.71M-130.76M-130.56M-131.00M-122.00M-235.00M1.27B3.06B3.56B4.23B2.45B1.17B-366.00M-1.87B-2.01B-1.27B-1.36B-70.00M--1.05B-907.00M-260.00M-857.00M-1.39B
EBITDA -----------------------------924.00M-760.00M-135.00M-724.00M-1.26B
Interest Expense ----------------------------1.00M1.00M08.00M17.00M
Pretax Income -----------------------------964.00M-818.00M-187.00M-799.00M-1.33B
Tax Provision ----------------------------7.00M7.00M13.00M27.00M9.00M
Net Income -----72.38M-90.60M-80.33M--132.58M-134.94M-123.22M--124.00M-117.00M-233.00M1.22B2.78B3.33B3.66B2.20B1.04B79.00M-1.38B-3.63B-1.18B-1.28B13.00M--971.00M-825.00M-200.00M-826.00M-1.34B
Diluted EPS -------------0.35-0.31-0.592.846.467.708.585.242.530.19-3.62-9.53-3.07-3.330.03--2.52-2.13-0.51-2.11-3.40
R&D Expense ----90.12M104.48M109.05M-130.41M128.31M119.64M-115.00M152.00M344.00M401.00M421.00M521.00M554.00M710.00M820.00M1.13B1.15B1.16B1.06B1.22B1.14B-856.00M700.00M801.00M-649.00M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue ---60.21M--18.88B6.75B3.20B1.92B
Cost of Revenue ------5.42B4.69B1.46B868.00M
Gross Profit ------13.46B2.06B1.74B1.05B
Operating Expenses ------4.04B6.30B5.68B4.13B
Operating Income -223.77M-269.36M-413.27M-546.00M-763.00M-9.42B-4.24B-3.94B-3.07B
EBITDA ------9.77B-3.62B-3.39B-2.54B
Interest Expense ------29.00M38.00M24.00M10.00M
Pretax Income ------9.57B-3.94B-3.61B-2.77B
Tax Provision ------1.21B772.00M-46.00M54.00M
Net Income -216.21M-255.92M-384.73M-514.00M-747.00M-8.36B-4.71B-3.56B-2.82B
Diluted EPS ----1.55-1.9628.2920.12-12.33-9.28-
R&D Expense 274.72M410.46M454.08M496.00M1.37B1.99B3.29B4.84B4.54B3.13B

Compounded Sales Growth

5 Years:-53.30%
1 Year:260.20%

Compounded Profit Growth

5 Years:-44.58%
1 Year:-

Stock Price Performance

1 Year:+77.67%
6 Months:+90.67%
3 Months:-11.91%
1 Month:+3.22%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2015Dec 2016Dec 2017Dec 2018Jan 2019Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --1.08B1.96B2.02B1.59B7.34B-25.86B18.43B14.14B12.34B
Current Assets --------13.43B10.32B8.10B6.54B
Cash & Equivalents 159.04M50.08M134.86M658.36M-236.00M2.62B-3.21B2.91B1.93B2.60B
Inventory --------949.00M202.00M117.00M153.00M
Receivables --------1.39B892.00M358.00M184.00M
Total Liabilities --459.19M431.91M-414.61M4.78B-6.74B4.57B3.24B3.69B
Current Liabilities --191.46M222.80M-143.12M4.39B-4.92B3.02B2.21B1.99B
Long Term Debt -----------590.00M
Total Debt --------1.20B1.24B747.00M1.30B
Total Equity -149.76M-334.81M-551.37M1.53B-1.18B2.56B-19.12B13.85B10.90B8.65B
Shares Outstanding --------385.00M382.00M386.00M394.00M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 66.73M-331.48M-330.87M-459.00M2.03B-4.98B-3.12B-3.00B-1.87B
Investing Cash Flow -648.61M417.36M-373.09M-15.00M-1.67B--5.18B4.21B1.95B1.95B
Financing Cash Flow 472.91M168.00K1.23B52.00M2.03B--3.45B-1.38B56.00M593.00M
Capital Expenditure -33.14M-58.40M-105.77M-32.00M-68.00M--400.00M-707.00M-1.05B-202.00M
Free Cash Flow 33.59M-389.88M-436.63M-491.00M1.96B-4.58B-3.83B-4.05B-2.08B
Net Change in Cash -------3.64B-289.00M-999.00M666.00M
Share Buybacks ---00857.00M3.33B1.15B02.00M

Ratios (Annual)

Figures in %.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ------71.3%30.5%54.2%54.8%
Operating Margin % ----906.8%--49.9%-62.8%-123.3%-159.9%
Net Margin % ----853.7%--44.3%-69.8%-111.3%-146.8%
ROE % 64.6%46.4%-25.1%-43.7%-29.2%-43.7%-34.0%-32.7%-32.6%
ROCE % --30.2%-23.8%-37.8%-25.9%-45.0%-27.5%-33.1%-29.7%

Shareholding Pattern

Insiders
7.30%
Institutions
78.83%
Public Float
85.05%

Top Institutional Holders

#Holder% HeldSharesValue
1 FMR, LLC 11.51% 45.67M $2.16B
2 Blackrock Inc. 7.47% 29.64M $1.40B
3 Vanguard Capital Management LLC 5.76% 22.87M $1.08B
4 BAILLIE GIFFORD & CO 5.04% 19.99M $943.13M
5 Capital World Investors 4.71% 18.70M $882.34M
6 Vanguard Portfolio Management LLC 3.94% 15.62M $736.94M
7 State Street Corporation 3.75% 14.86M $701.31M
8 Geode Capital Management, LLC 2.38% 9.44M $445.24M
9 Two Sigma Investments, LP 2.29% 9.09M $428.79M
10 Morgan Stanley 2.13% 8.47M $399.76M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MRNA

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks